CAH:NYE-Cardinal Health Inc (USD)

COMMON STOCK | Medical Distribution | NYE

Last Closing Price

USD 55.61

Change

0.00 (0.00)%

Market Cap

USD 15.15B

Volume

2.24M

Avg Analyst Target

USD 59.33 (+6.70%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Cardinal Health Inc (CAH) Stock Analysis:
Based on the Cardinal Health Inc stock forecasts from 4 analysts, the average analyst target price for Cardinal Health Inc is USD 59.33 over the next 12 months. Cardinal Health Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Cardinal Health Inc is Slightly Bearish, which is based on 7 positive signals and 9 negative signals. At the last closing, Cardinal Health Inc’s stock price was USD 55.61. Cardinal Health Inc’s stock price has changed by -4.56% over the past week, -11.67% over the past month and -1.30% over the last year.

About

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laborator ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-15 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MCK McKesson Corporation

N/A

USD47.13B 35.96 18.24
ABC AmerisourceBergen Corporation

N/A

USD32.02B 19.83 10.55
PBH Prestige Consumer Healthcare I..

N/A

USD2.85B 15.26 12.01
OMI Owens & Minor Inc

N/A

USD2.74B 12.26 14.34
7459 Medipal Holdings Corp

N/A

N/A N/A N/A

ETFs Containing CAH

Symbol Name Weight Mer Price(Change) Market Cap
ESGL Invesco ESG Revenue ETF 0.00 % 0.40 %

N/A

USD0.03B
RDIV Invesco S&P Ultra Dividen.. 0.00 % 0.39 %

N/A

USD1.03B
WBIY WBI Power Factor High Div.. 0.00 % 0.70 %

N/A

USD0.07B
IVFVC Ivy Focused Value NextSha.. 0.00 % 0.78 %

N/A

USD8.39M
SUSB iShares ESG 1-5 Year USD .. 0.00 % 0.12 %

N/A

USD0.97B
UDIV:CA Manulife Smart U.S. Divid.. 0.00 % 0.37 %

N/A

N/A
GBDV Global Beta ETF Trust - G.. 0.00 % 0.29 %

N/A

N/A
UDIV-B:CA Manulife Smart U.S. Divid.. 0.00 % 0.31 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Distribution)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.00% 60% D- 89% B+
Dividend Return 0.95% 100% A+ 50% F
Total Return 8.95% 60% D- 89% B+
Trailing 12 Months  
Capital Gain -1.30% 20% F 73% C
Dividend Return 3.48% 100% A+ 59% F
Total Return 2.19% 20% F 76% C
Trailing 5 Years  
Capital Gain -23.43% 20% F 23% F
Dividend Return 13.20% 100% A+ 51% F
Total Return -10.24% 20% F 21% F
Average Annual (5 Year Horizon)  
Capital Gain -4.03% 20% F 11% F
Dividend Return 3.54% 100% A+ 72% C-
Total Return -0.49% 20% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 16.14% 80% B- 67% D+
Risk Adjusted Return -3.05% 20% F 16% F
Market Capitalization 15.15B 60% D- 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Distribution)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 28.90 40% F 21% F
Price/Book Ratio 16.07 40% F 4% F
Price / Cash Flow Ratio 6.24 100% A+ 53% F
EV/EBITDA 80.37 20% F 4% F
Management Effectiveness  
Return on Equity 37.35% 100% A+ 90% A-
Return on Invested Capital 9.19% 40% F 65% D
Return on Assets 2.62% 20% F 51% F
Debt to Equity Ratio 299.55% 40% F 10% F
Technical Ratios  
Dividend Yield 3.57% 100% A+ 28% F
Short Ratio 2.69 80% B- 41% F
Short Percent 3.14% 40% F 54% F
Beta 0.92 20% F 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector